Technology ID
TAB-3888

Clinical Outcome Predictors for Mantle Cell Lymphoma

E-Numbers
E-131-2016-0
Lead Inventor
Staudt, Louis (NCI)
Co-Inventors
Scott, David (British Columbia Cancer Agency)
Wright, George (NCI)
Rosenwald, Andreas (University Of Wurzburg)
Abrisqueta, Pau (British Columbia Cancer Agency)
Braziel, Rita (Oregon Health and Science University (OHSU))
Guerri, Elias (University of Barcelona)
Chan, Wing (City of Hope Medical Center)
Connors, Joseph (British Columbia Cancer Agency)
Villa, Diego (British Columbia Cancer Agency)
Fu, Kai (University of Nebraska Medical Center)
Gascoyne, Randy (British Columbia Cancer Agency)
Greiner, Timothy (University of Nebraska Medical Center)
Jaffe, Elaine (NCI)
Slack, Graham (British Columbia Cancer Agency)
Cook, James (Cleveland Clinic)
Delabie, Jan (University Health Network, University of Toronto)
Ott, German (Robert Bosch Stiftung)
Rimsza, Lisa (Mayo Clinic Arizona)
Weisenburger, Dennis (City of Hope Medical Center)
Mottok, Anja (British Columbia Cancer Agency)
Jares, Pedro (Hospital Clinic de Barcelona)
Applications
Diagnostics
Therapeutic Areas
Oncology
Development Stages
Clinical Phase I
Lead IC
NCI
ICs
NCI

Mantle cell lymphoma (MCL) is a group of aggressive B-cell lymphomas displaying heterogeneous outcomes after treatment.  Some patients have the slowly progressing disease that does not require immediate treatment, while others have a disease that rapidly progresses despite highly aggressive treatment. A number of prognostic tools have been described to determine whether patients have slow or rapidly progressing diseases, including the mantle cell lymphoma International Prognostic Index (MIPI) and biomarkers, such as KI-67.

Researchers have discovered a novel method of predicting a MCL patient’s overall survival prognosis (poor, intermediate, or good) by measuring the gene expression profile of a specific subset of biomarkers from a biopsy and using a set of statistical algorithms to analyze the results and produce a “survival score”.  The survival score enables a physician to determine the best course of treatment, such as a less aggressive or more aggressive treatment protocol or an experimental treatment that would be the most beneficial for an MCL patient.

Competitive Advantages:

  • Does not require fresh frozen samples, utilizes formalin-fixed paraffin-embedded (FFPE) samples
  • In contrast to current KI-67 assay, the subject technology is reproducible

Commercial Applications:

  • Mantle cell lymphoma prognostic tool

Request More Info

Licensing Contact:
Bhattacharya, Ramona
ramona.bhattacharya@nih.gov

Related Inventions

  • E-108-2004
  • E-256-2008
  • E-750-2013

Patents

  • Patent Cooperation Treaty
    (PCT) PCT/US2017/028628
    Filed on 2017-04-20
  • US
    Provisional (PRV) 62/325,213
    Filed on 2016-04-20
  • Australia
    National Stage 2017254645
    Filed on 2018-10-05
  • Canada
    National Stage 3021569
    Filed on 2017-04-20
  • European Patent
    National Stage 17724960.4
    Filed on 2018-10-10
  • Japan
    National Stage 2018-555639
    Filed on 2017-04-20
  • US Patent 11,725,248
    Filed on 2018-10-19
  • Switzerland
    European patent (EP) 17724960.4
    Filed on 2018-10-10
  • Germany
    European patent (EP) 17724960.4
    Filed on 2018-10-10
  • Spain
    European patent (EP) 17724960.4
    Filed on 2018-10-10
  • France
    European patent (EP) 17724960.4
    Filed on 2018-10-10
  • United Kingdom
    European patent (EP) 17724960.4
    Filed on 2018-10-10
  • Italy
    European patent (EP) 17724960.4
    Filed on 2018-10-10

Publications

Collaborations

  • Licensing
  • Collaboration
Date Published
Date Updated